Nanoparticle biointerfacing by platelet membrane cloaking
Che-Ming J Hu, Ronnie H Fang, Kuei-Chun Wang, Brian T Luk, Soracha Thamphiwatana, Diana Dehaini, Phu Nguyen, Pavimol Angsantikul, Cindy H Wen, Ashley V Kroll, Cody Carpenter, Manikantan Ramesh, Vivian Qu, Sherrina H Patel, Jie Zhu, William Shi, Florence M Hofman, Thomas C Chen, Weiwei Gao, Kang Zhang, Shu Chien, Liangfang Zhang, Che-Ming J Hu, Ronnie H Fang, Kuei-Chun Wang, Brian T Luk, Soracha Thamphiwatana, Diana Dehaini, Phu Nguyen, Pavimol Angsantikul, Cindy H Wen, Ashley V Kroll, Cody Carpenter, Manikantan Ramesh, Vivian Qu, Sherrina H Patel, Jie Zhu, William Shi, Florence M Hofman, Thomas C Chen, Weiwei Gao, Kang Zhang, Shu Chien, Liangfang Zhang
Abstract
Development of functional nanoparticles can be encumbered by unanticipated material properties and biological events, which can affect nanoparticle effectiveness in complex, physiologically relevant systems. Despite the advances in bottom-up nanoengineering and surface chemistry, reductionist functionalization approaches remain inadequate in replicating the complex interfaces present in nature and cannot avoid exposure of foreign materials. Here we report on the preparation of polymeric nanoparticles enclosed in the plasma membrane of human platelets, which are a unique population of cellular fragments that adhere to a variety of disease-relevant substrates. The resulting nanoparticles possess a right-side-out unilamellar membrane coating functionalized with immunomodulatory and adhesion antigens associated with platelets. Compared to uncoated particles, the platelet membrane-cloaked nanoparticles have reduced cellular uptake by macrophage-like cells and lack particle-induced complement activation in autologous human plasma. The cloaked nanoparticles also display platelet-mimicking properties such as selective adhesion to damaged human and rodent vasculatures as well as enhanced binding to platelet-adhering pathogens. In an experimental rat model of coronary restenosis and a mouse model of systemic bacterial infection, docetaxel and vancomycin, respectively, show enhanced therapeutic efficacy when delivered by the platelet-mimetic nanoparticles. The multifaceted biointerfacing enabled by the platelet membrane cloaking method provides a new approach in developing functional nanoparticles for disease-targeted delivery.
Figures
![Extended Data Fig. 1. Schematic preparation of…](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/4871317/bin/nihms715471f5.jpg)
![Extended Data Fig. 2. PNP preparation and…](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/4871317/bin/nihms715471f6.jpg)
![Extended Data Fig. 3. Overall protein content…](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/4871317/bin/nihms715471f7.jpg)
![Extended Data Fig. 4. Platelet membrane sidedness…](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/4871317/bin/nihms715471f8.jpg)
![Extended Data Fig. 5. PNP binding to…](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/4871317/bin/nihms715471f9.jpg)
![Extended Data Fig. 6. Pharmacokinetics, biodistribution, and…](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/4871317/bin/nihms715471f10.jpg)
![Extended Data Fig. 7. PNP targeting of…](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/4871317/bin/nihms715471f11.jpg)
![Extended Data Fig. 8. Characterizations of drug-loaded…](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/4871317/bin/nihms715471f12.jpg)
![Extended Data Fig. 9. Treatment of an…](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/4871317/bin/nihms715471f13.jpg)
![Extended Data Fig. 10. PNP adherence to…](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/4871317/bin/nihms715471f14.jpg)
![Figure 1. Preparation and characterization of PNPs](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/4871317/bin/nihms715471f1.jpg)
![Figure 2. Collagen binding and immunocompatibility](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/4871317/bin/nihms715471f2.jpg)
![Figure 3. Adherence to damaged human and…](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/4871317/bin/nihms715471f3.jpg)
![Figure 4. Binding to platelet-adhering pathogens](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/4871317/bin/nihms715471f4.jpg)
References
- Pelaz B, et al. Interfacing engineered nanoparticles with biological systems: anticipating adverse nanobio interactions. Small. 2013;9:1573–1584.
- Salvati A, et al. Transferrin-functionalized nanoparticles lose their targeting capabilities when a biomolecule corona adsorbs on the surface. Nature Nanotech. 2013;8:137–143.
- Tenzer S, et al. Rapid formation of plasma protein corona critically affects nanoparticle pathophysiology. Nature Nanotech. 2013;8:772–781.
- Born GV, Cross MJ. The aggregation of blood platelets. J. Physiol. 1963;168:178–195.
- Kieffer N, Phillips DR. Platelet membrane-glycoproteins - functions in cellular interactions. Annu. Rev. Cell Biol. 1990;6:329–357.
- Fitzgerald JR, Foster TJ, Cox D. The interaction of bacterial pathogens with platelets. Nat. Rev. Microbiol. 2006;4:445–457.
- Yeaman MR. Platelets in defense against bacterial pathogens. Cell. Mol. Life. Sci. 2010;67:525–544.
- Peters D, et al. Targeting atherosclerosis by using modular, multifunctional micelles. Proc. Natl. Acad. Sci. U.S.A. 2009;106:9815–9819.
- Chan JM, et al. Spatiotemporal controlled delivery of nanoparticles to injured vasculature. Proc. Natl. Acad. Sci. U.S.A. 2010;107:2213–2218.
- Bertram JP, et al. Intravenous hemostat: nanotechnology to halt bleeding. Sci. Trans. Med. 2009;1:11ra22.
- Modery-Pawlowski CL, et al. Approaches to synthetic platelet analogs. Biomaterials. 2013;34:526–541.
- Simberg D, et al. Biomimetic amplification of nanoparticle homing to tumors. Proc. Natl. Acad. Sci. U.S.A. 2007;104:932–936.
- Anselmo AC, et al. Platelet-like nanoparticles: mimicking shape, flexibility, and surface biology of platelets to target vascular injuries. ACS Nano. 2014
- Olsson M, Bruhns P, Frazier WA, Ravetch JV, Oldenborg PA. Platelet homeostasis is regulated by platelet expression of CD47 under normal conditions and in passive immune thrombocytopenia. Blood. 2005;105:3577–3582.
- Sims PJ, Rollins SA, Wiedmer T. Regulatory control of complement on blood-platelets - modulation of platelet procoagulant responses by a membrane inhibitor of the C5b-9 Complex. J. Biol. Chem. 1989;264:19228–19235.
- Nieswandt B, Watson SP. Platelet-collagen interaction: is GPVI the central receptor? Blood. 2003;102:449–461.
- Hu CM, et al. Erythrocyte membrane-camouflaged polymeric nanoparticles as a biomimetic delivery platform. Proc. Natl. Acad. Sci. U.S.A. 2011;108:10980–10985.
- Hu CM, Fang RH, Copp J, Luk BT, Zhang L. A biomimetic nanosponge that absorbs pore-forming toxins. Nature Nanotech. 2013;8:336–340.
- Hu CM, Fang RH, Luk BT, Zhang L. Nanoparticle-detained toxins for safe and effective vaccination. Nature Nanotech. 2013;8:933–938.
- Gachet C, et al. Alpha IIb beta 3 integrin dissociation induced by EDTA results in morphological changes of the platelet surface-connected canalicular system with differential location of the two separate subunits. J. Cell. Biol. 1993;120:1021–1030.
- Luk B, et al. Interfacial interactions between natural RBC membranes and synthetic polymeric nanoparticles. Nanoscale. 2013;6:2730–2737.
- Hughes CE, et al. CLEC-2 activates Syk through dimerization. Blood. 2010;115:2947–2955.
- Kalluri R. Basement membranes: structure, assembly and role in tumour angiogenesis. Nature Rev. Cancer. 2003;3:422–433.
- Rodriguez PL, et al. Minimal “self” peptides that inhibit phagocytic clearance and enhance delivery of nanoparticles. Science. 2013;339:971–975.
- Law SKA, Dodds AW. The internal thioester and the covalent binding properties of the complement proteins C3 and C4. Protein Sci. 1997;6:263–274.
- Terstappen LWMM, Nguyen M, Lazarus HM, Medof ME. Expression of the DAF (CD55) and CD59 antigens during normal hematopoietic-cell differentiation. J. Leukocyte Biol. 1992;52:652–660.
- Andersen AJ, Hashemi SH, Andresen TL, Hunter AC, Moghimi SM. Complement: alive and kicking nanomedicines. J. Biomed. Nanotech. 2009;5:364–372.
- Siboo IR, Chambers HF, Sullam PM. Role of SraP, a serine-rich surface protein of Staphylococcus aureus, in binding to human platelets. Infect. Immun. 2005;73:2273–2280.
- Kamaly N, et al. Development and in vivo efficacy of targeted polymeric inflammation-resolving nanoparticles. Proc. Natl. Acad. Sci. U.S.A. 2013;110:6506–6511.
- Hu CM, et al. ‘Marker-of-self’ functionalization of nanoscale particles through a top-down cellular membrane coating approach. Nanoscale. 2013;5:2664–2668.
Source: PubMed